TROPION-Lung01 Study Design and Baseline demographics
•
Background: Unmet Need in HR+/HER2- MBC
•
•
HR+/HER2- breast cancer is the most common subtype of breast cancer, accounting for
60-70% of all cases1
Despite new therapeutic options becoming available, there remains an unmet need after
endocrine therapy and one line of systemic therapy for patients with HR+/HER2- MBC2-5
Chemotherapy is utilised widely for management of endocrine-resistant HR+/HER2- MBC,
but is associated with low response rate, poor prognosis, and significant toxicity including
myelosuppression and peripheral neuropathy6
TROP2-directed ADCs can have significant toxicities including diarrhoea, neutropenia and
thrombocytopenia7,8
Daiichi-Sankyo
ADC, antibody-drug conjugate; HER2-, human epidermal growth factor receptor 2-negative; HR+, hormone receptor-positive;
MBC, metastatic breast cancer; TROP2, trophoblast cell surface antigen 2.
1. Sung H et al. CA Cancer J Clin 2021;71:209-49; 2. Gennari A, et al. Ann Oncol 2021;32:1475-1495;
3. Wolff AC, et al. J Clin Oncol 2023;41:3867-72; 4. Moy B, et all. J Clin Oncol 2023;41:1318-20;
5. Moy B, et al. J Clin Oncol 2022;40:3088-90; 6. Kuderer NM, et al. Nat Rev Clin Oncol 2022;19:681-97;
7. Rugo HS, et al. J Clin Oncol 2022;40:3365-76; 8. Yin Y et al. Mini Oral at ESMO 2023; presentation 380MO.
24View entire presentation